ZA979706B - Nicotinic agents in addiction theraphy - Google Patents
Nicotinic agents in addiction theraphyInfo
- Publication number
- ZA979706B ZA979706B ZA979706A ZA979706A ZA979706B ZA 979706 B ZA979706 B ZA 979706B ZA 979706 A ZA979706 A ZA 979706A ZA 979706 A ZA979706 A ZA 979706A ZA 979706 B ZA979706 B ZA 979706B
- Authority
- ZA
- South Africa
- Prior art keywords
- theraphy
- addiction
- nicotinic agents
- nicotinic
- agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2880496P | 1996-10-30 | 1996-10-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA979706B true ZA979706B (en) | 1999-04-29 |
Family
ID=21845528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA979706A ZA979706B (en) | 1996-10-30 | 1997-10-29 | Nicotinic agents in addiction theraphy |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6235734B1 (de) |
| EP (1) | EP0937077B1 (de) |
| JP (2) | JP3621707B2 (de) |
| AP (1) | AP9701125A0 (de) |
| AR (1) | AR008901A1 (de) |
| AT (1) | ATE326468T1 (de) |
| AU (1) | AU4394897A (de) |
| DE (1) | DE69735891T2 (de) |
| ES (1) | ES2264169T3 (de) |
| GT (1) | GT199700115A (de) |
| HR (1) | HRP970567A2 (de) |
| ID (1) | ID18741A (de) |
| MA (1) | MA26445A1 (de) |
| PA (1) | PA8440201A1 (de) |
| TN (1) | TNSN97168A1 (de) |
| WO (1) | WO1998018798A1 (de) |
| ZA (1) | ZA979706B (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6717030B2 (en) * | 1998-07-06 | 2004-04-06 | The Regents Of The University Of California | Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse |
| IL137937A0 (en) * | 1999-08-27 | 2001-10-31 | Pfizer Prod Inc | A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
| US20010036943A1 (en) * | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| US20020010192A1 (en) * | 2000-06-02 | 2002-01-24 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| US20020016334A1 (en) * | 2000-07-31 | 2002-02-07 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) |
| AU2002365314A1 (en) | 2001-11-30 | 2003-06-10 | Pfizer Products Inc. | Aryl fused azapolycyclic compounds |
| SE0104463D0 (sv) * | 2001-12-29 | 2001-12-29 | Carlbiotech Ltd As | Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister |
| US20030162770A1 (en) | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| US20040224962A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| US20040224963A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
| WO2005000806A2 (en) * | 2003-06-10 | 2005-01-06 | Georgetown University | Ligands for nicotinic acetylcholine receptors, and methods of making and using them |
| CA2529193A1 (en) | 2003-07-21 | 2005-01-27 | Pfizer Products Inc. | Nicotine addiction reducing heteroaryl fused azapolycyclic compounds |
| US20050234024A1 (en) * | 2004-04-14 | 2005-10-20 | Clarke David E | Materials and methods for the treatment of ulcerative colitis |
| US7135933B2 (en) * | 2004-09-29 | 2006-11-14 | Intelliserv, Inc. | System for adjusting frequency of electrical output pulses derived from an oscillator |
| ES2306250T3 (es) * | 2004-12-07 | 2008-11-01 | Pfizer Products Incorporated | Derivados de 1,2,3,3a,8,8a-hexahidro-2,7a-diaza-ciclopenta(a)indan-7-ona que se unen a sitios receptores nicotinicos neuronales especificos de acetilcolina y son utiles para modular la funcion colinergica. |
| US20060211649A1 (en) * | 2005-03-21 | 2006-09-21 | Eric Marchewitz | Use of cytisine for enhancing physical performance |
| US20070134169A1 (en) * | 2005-12-11 | 2007-06-14 | Rabinoff Michael D | Methods for smoking cessation or alcohol cessation or other addiction cessation |
| EP1976519A2 (de) * | 2006-01-27 | 2008-10-08 | Yale University | Cytisin- und acetylcholin-analoge und -verfahren zur behandlung von stimmungsschwankungen |
| WO2007115092A2 (en) * | 2006-03-29 | 2007-10-11 | Georgetown University | 10-substituted cytisine derivatives and methods of use thereof |
| US7404725B2 (en) * | 2006-07-03 | 2008-07-29 | Hall David R | Wiper for tool string direct electrical connection |
| US8061443B2 (en) * | 2008-04-24 | 2011-11-22 | Schlumberger Technology Corporation | Downhole sample rate system |
| CN103119041A (zh) | 2009-12-22 | 2013-05-22 | 雅芳产品公司 | 桩蛋白刺激组合物及其化妆品用途 |
| US20110159125A1 (en) | 2009-12-29 | 2011-06-30 | Avon Products, Inc. | CGRP Compositions and Uses Thereof |
| FR2992315B1 (fr) * | 2012-06-25 | 2014-08-08 | Pf Medicament | Derives utiles dans le traitement de maladies du systeme nerveux central |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| CN102952134B (zh) * | 2012-12-05 | 2015-01-07 | 苏州药明康德检测检验有限责任公司 | 含二氟甲基的金雀花碱衍生物及制备方法和抗癌作用研究 |
| RU2630958C2 (ru) * | 2015-12-29 | 2017-09-15 | федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" (МФТИ) | Новые макроциклические соединения, содержащие природное 3,7-диазабицикло[3.3.1]нонановое ядро и способ их получения |
| GB201602145D0 (en) | 2016-02-05 | 2016-03-23 | Achieve Pharma Uk Ltd | Salt |
| GB2558700B (en) | 2016-08-19 | 2022-07-27 | Univ Bristol | 4-substituted Analogs of Cytisine |
| CA3070055A1 (en) * | 2017-07-24 | 2019-01-31 | Achieve Pharma Uk Limited | Cytisine salts |
| MX2022002882A (es) * | 2019-09-12 | 2022-05-10 | Achieve Life Sciences Inc | Composiciones que comprenden citisina en el tratamiento y/o prevencion de la adiccion en sujetos que lo necesitan. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2125699B (en) | 1982-02-22 | 1986-02-12 | Bruss Ni Sanitarno Gigieniches | Medicinal preparation having antinicotine effect and method for obtention thereof |
| US4835162A (en) * | 1987-02-12 | 1989-05-30 | Abood Leo G | Agonists and antagonists to nicotine as smoking deterents |
| US5242916A (en) * | 1992-07-07 | 1993-09-07 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| TW261531B (de) | 1993-10-28 | 1995-11-01 | Dynagen Inc | |
| EP0853621A1 (de) * | 1995-09-22 | 1998-07-22 | Novo Nordisk A/S | Neue substituierte azazyklische oder azabizyklische verbindungen |
-
1997
- 1997-10-15 ES ES97942166T patent/ES2264169T3/es not_active Expired - Lifetime
- 1997-10-15 AT AT97942166T patent/ATE326468T1/de not_active IP Right Cessation
- 1997-10-15 WO PCT/IB1997/001282 patent/WO1998018798A1/en active IP Right Grant
- 1997-10-15 DE DE69735891T patent/DE69735891T2/de not_active Expired - Fee Related
- 1997-10-15 EP EP97942166A patent/EP0937077B1/de not_active Expired - Lifetime
- 1997-10-15 US US09/297,109 patent/US6235734B1/en not_active Expired - Fee Related
- 1997-10-15 AU AU43948/97A patent/AU4394897A/en not_active Abandoned
- 1997-10-15 JP JP52022898A patent/JP3621707B2/ja not_active Expired - Fee Related
- 1997-10-23 AP APAP/P/1997/001125A patent/AP9701125A0/en unknown
- 1997-10-24 PA PA19978440201A patent/PA8440201A1/es unknown
- 1997-10-24 HR HR60/028,804A patent/HRP970567A2/hr not_active Application Discontinuation
- 1997-10-27 GT GT199700115A patent/GT199700115A/es unknown
- 1997-10-28 AR ARP970104980A patent/AR008901A1/es unknown
- 1997-10-28 ID IDP973538A patent/ID18741A/id unknown
- 1997-10-29 TN TNTNSN97168A patent/TNSN97168A1/fr unknown
- 1997-10-29 MA MA24849A patent/MA26445A1/fr unknown
- 1997-10-29 ZA ZA979706A patent/ZA979706B/xx unknown
-
2001
- 2001-02-14 US US09/783,443 patent/US6630467B2/en not_active Expired - Fee Related
-
2004
- 2004-09-21 JP JP2004273910A patent/JP2005060403A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0937077B1 (de) | 2006-05-17 |
| AU4394897A (en) | 1998-05-22 |
| EP0937077A1 (de) | 1999-08-25 |
| TNSN97168A1 (fr) | 2005-03-15 |
| ATE326468T1 (de) | 2006-06-15 |
| ES2264169T3 (es) | 2006-12-16 |
| DE69735891D1 (de) | 2006-06-22 |
| PA8440201A1 (es) | 2000-05-24 |
| WO1998018798A1 (en) | 1998-05-07 |
| JP2000505809A (ja) | 2000-05-16 |
| GT199700115A (es) | 1999-04-20 |
| AR008901A1 (es) | 2000-02-23 |
| JP2005060403A (ja) | 2005-03-10 |
| DE69735891T2 (de) | 2006-12-14 |
| AP9701125A0 (en) | 1997-10-31 |
| US6235734B1 (en) | 2001-05-22 |
| ID18741A (id) | 1998-05-07 |
| MA26445A1 (fr) | 2004-12-20 |
| JP3621707B2 (ja) | 2005-02-16 |
| HRP970567A2 (en) | 1998-10-31 |
| US6630467B2 (en) | 2003-10-07 |
| US20030065173A1 (en) | 2003-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA979706B (en) | Nicotinic agents in addiction theraphy | |
| DE69834346D1 (en) | Proteinexpression in baculovirus-vektor expressionsystemen | |
| HRP970330A2 (en) | Cycloalkano pyridines | |
| SG46782A1 (en) | Bicyclic-fused pyridines | |
| AP9801175A0 (en) | Quinoline and quinoline compounds useful in therapy | |
| DE69927412D1 (en) | Phosphitadditive in polyolefinen | |
| PL335258A1 (en) | Arylamine-condensed pyridines and pyrimidines | |
| EP1037635A4 (de) | Verbindungen umd methoden | |
| GB9609641D0 (en) | Compounds useful in therapy | |
| HK1045639B (zh) | 滑動復原設備 | |
| PL327610A1 (en) | Quinoline and quinozoline compounds useful in therapy | |
| GB9717766D0 (en) | Methods | |
| GB9822063D0 (en) | Hinge suitable for use in afoldable device | |
| IL136754A0 (en) | Improvements in hosiery | |
| HUP0001110A3 (en) | 3-pyridyl enantiomers and their use as analgesics | |
| GB9412294D0 (en) | Improvements in cutting devices | |
| DE69732623D1 (en) | Analogsignalmultiplexer in strombetriebsart | |
| GB2321857B (en) | Improvements in filters | |
| GB9725953D0 (en) | Compounds useful in therapy | |
| GB9707742D0 (en) | Methods | |
| PL339259A1 (en) | Gonadothropin expression in dictostelium | |
| DE69531611D1 (en) | Lactone-stabile camptothecin oder 7 - ethyl camptothecin - formulierung in dimethylisosorbid oder dimethylacetamid | |
| GB9722287D0 (en) | Compounds useful in therapy | |
| GB9604400D0 (en) | Compounds useful in therapy | |
| GB9602100D0 (en) | Decals |